EFG Asset Management North America Corp. Sells 8,563 Shares of Natera, Inc. $NTRA

Key Points

• EFG Asset Management North America Corp. reduced its stake in Natera, Inc. by 19.4%, selling 8,563 shares, leaving them with 35,488 shares valued at approximately $5 million.
• Natera reported a loss of ($0.74) earnings per share for the most recent quarter, missing analysts' expectations, despite a year-over-year revenue increase of 32.2% to $546.6 million.
• Insider trading activity showed significant selling, as company executives sold a combined total of over 52,000 shares in the past three months.

EFG Asset Management North America Corp. cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 19.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,488 shares of the medical research company's stock after selling 8,563 shares during the period. Natera accounts for about 0.8% of EFG Asset Management North America Corp.'s investment portfolio, making the stock its 27th biggest holding. EFG Asset Management North America Corp.'s holdings in Natera were worth $5,019,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Cinctive Capital Management LP acquired a new stake in shares of Natera in the 1st quarter valued at approximately $3,011,000. Alliancebernstein L.P. raised its position in Natera by 3.2% during the first quarter. Alliancebernstein L.P. now owns 792,410 shares of the medical research company's stock worth $112,055,000 after acquiring an additional 24,348 shares in the last quarter. AQR Capital Management LLC lifted its stake in Natera by 26.3% in the first quarter. AQR Capital Management LLC now owns 1,193,981 shares of the medical research company's stock valued at $165,074,000 after acquiring an additional 248,470 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in Natera by 10.3% in the first quarter. Advisors Asset Management Inc. now owns 8,882 shares of the medical research company's stock valued at $1,256,000 after acquiring an additional 826 shares during the last quarter. Finally, Amundi grew its position in shares of Natera by 15.2% in the 1st quarter. Amundi now owns 498,914 shares of the medical research company's stock valued at $69,204,000 after acquiring an additional 65,728 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Stock Down 1.1%

Shares of NASDAQ:NTRA opened at $167.53 on Thursday. The stock has a market cap of $22.99 billion, a price-to-earnings ratio of -87.71 and a beta of 1.68. The business's 50 day moving average is $154.38 and its 200 day moving average is $153.97. Natera, Inc. has a 12-month low of $110.57 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the previous year, the business earned ($0.30) earnings per share. The firm's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 3,045 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total transaction of $418,383.00. Following the sale, the chief financial officer owned 65,430 shares of the company's stock, valued at approximately $8,990,082. This represents a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the sale, the director directly owned 8,118 shares of the company's stock, valued at $1,358,628.48. This represents a 34.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 52,344 shares of company stock valued at $7,771,750 in the last three months. Insiders own 5.63% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NTRA. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the company an "outperform" rating in a report on Tuesday. Barclays reiterated an "overweight" rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Finally, Piper Sandler restated an "overweight" rating and set a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.